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Abstract
Background: Activation of the RON receptor tyrosine kinase, a member of the c-MET family, regulates tumorigenic
phenotypes. The RON extracellular domains are critical in regulating these activities. The objective of this study was
to determine the role of the first IPT domain in regulating RON-mediated tumorigenic activities and the underlying
mechanisms.
Results: Two RON variants, RON160 and RON
E5/6in with deletion and insertion in the first IPT domain, respectively,
were molecularly cloned. RON160 was a splicing variant generated by deletion of 109 amino acids encoded by
exons 5 and 6. In contrast, RON
E5/6in was derived from a transcript with an insertion of 20 amino acids between
exons 5 and 6. Both RON160 and RON
E5/6in were proteolytically matured into two-chain receptor and expressed on
the cell surface. RON160 was constitutively active with tyrosine phosphorylation. However, activation of RON
E5/6in
required ligand stimulation. Deletion resulted in the resistance of RON160 to proteolytic digestion by cell
associated trypsin-like enzymes. RON160 also resisted anti-RON antibody-induced receptor internalization. These
features contributed to sustained intracellular signaling cascades. On the other hand, RON
E5/6in was highly
susceptible to protease digestion, which led to formation of a truncated variant known as RONp110. RON
E5/6in also
underwent rapid internalization upon anti-RON antibody treatment, which led to signaling attenuation. Although
ligand-induced activation of RON
E5/6in partially caused epithelial to mesenchymal transition (EMT), it was RON160
that showed cell-transforming activities in cell focus formation and anchorage-independent growth. RON160-
mediated EMT is also associated with increased motile/invasive activity.
Conclusions: Alterations in the first IPT domain in extracellular region differentially regulate RON mediated
tumorigenic activities. Deletion of the first IPT results in formation of oncogenic variant RON160. Enhanced
degradation and internalization with attenuated signaling cascades could be the mechanisms underlying non-
tumorigenic features of RON
E5/6in.
Background
The RON (recepteur d’origine nantais) receptor tyrosine
kinase belongs to the MET proto-oncogene family [1,2],
which plays a critical role in epithelial cell homeostasis
and tumorigenic development [3]. Expression of RON
has been found mainly in cells of epithelial origin
although certain tissue macrophages and immune cells
also express the RON mRNA and protein [4-6]. Accu-
mulated evidences have indicated that aberrant RON
expression, characterized by protein overexpression and
generation of various variants, contributes to pathogen-
esis of epithelial cancers [7,8]. Immunohistochemical
staining has demonstrated that RON is overexpressed in
more than 40% of primary cancer samples from breast,
colon, and pancreatic tissues [4,9-11]. Increased RON
expression has also been considered as a validated prog-
nostic factor for predicting disease progression and
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any medium, provided the original work is properly cited.survival rate in certain cancer patients [10,12]. Although
RON gene mutations were not found in primary cancer
samples, aberrant splicing resulting in formation of var-
ious tumorigenic RON variants is frequently observed in
primary colon, breast, and brain tumors [7,13,14]. Func-
tional analysis has revealed that RON activation pro-
motes malignant phenotype of cancer cells [3]. In tumor
cells overexpressing RON, cells undergo epithelial to
mesenchymal transition (EMT) featured by spindle-like
morphology, diminished E-cadherin expression, and
increased vimentin expression [15,16]. EMT is a unique
phenotype observed in cancer stem cells and is a critical
process required for cancer metastasis [17]. Evidence
has also indicated that altered RON expression results
in increased survival and pro-apoptotic activity of
tumor cells [18,19]. These activities of RON help to
sustain tumor growth under hostile environment such
as hypoxia [3,19,20]. Recent studies further demon-
strate that abnormality in RON expression contributes
to acquired resistance of cancer cells to conventional
chemotherapeutics [21]. We have recently observed
that down-regulation of RON expression under
chronic hypoxia is a mechanism contributing to the
insensitivity of tumor cells towards small molecule
inhibitor-induced inhibitory or cytotoxic activities [22].
Clearly, aberrant RON expression is a pathogenic fac-
tor contributing to cancer development and malignant
progression. Such abnormality also provides the mole-
cular basis of targeting RON for potential therapeutic
intervention [23].
As described above, aberrant RON expression is fea-
tured by generation of biologically active RON variants
[7,13,14]. Currently, seven RON variants including
RON170, RON165, RON160, RON155, RONp110,
RON85, and RON52 have been identified in primary
cancer samples and in established cell lines [7,14,24].
One of the tumorigenic variants is RON160, which is
constitutively active and has oncogenic activities in
vivo [13]. RON160 is produced by a RON mRNA tran-
script through alternative splicing that eliminates 109
amino acids in the RON extracellular domain [13].
These amino acids are encoded by exons 5 and 6,
which constitute the first IPT domain in the RON b-
chain [25]. The b-chain extracellular sequences harbor
a cluster of four IPT units between sema and trans-
membrane segment [25-27]. The first IPT unit con-
tains 103 amino acids (from Pro
569 to Asp
671)a n di s
featured by immunoglobulin-like fold [25]. The func-
tions of the second and third IPT units are currently
unknown. The fourth IPT unit is critically important
in regulating RON protein maturation and cell surface
expression [28,29]. Currently, the mechanism of how
the deletion of the first IPT domain resulting in onco-
genic conversion is largely unknown. It is reasoned
that the deletion causes RON conformational change
and leads to spontaneous dimerization, which causes
constitutive receptor phosphorylation and increased
intracellular signaling activation [13].
The purpose of the present work is to determine the
role of the first IPT unit in the RON extracellular
sequences in regulating RON-mediated tumorigenic
activities in epithelial cells. By studying two RON var-
iants formed either by deletion of 109 amino acids
coded by exons 5 and 6 or by insertion of 20 amino
acids between exons 5 and 6, we observed striking dif-
ferences in biochemical and biological properties.
Clearly, deletion or insertion induced alterations in the
first IPT domain have different biological consequences,
which may have pathogenic implications in regulating
RON-mediated activities.
Materials and methods
Cell Lines and Reagents
Human colon (HT-29, SW620, and SW837), breast
(HCC-1937, MDA-MB231, T-47D, ZR-751, and MCF-
7), and pancreatic (BxPc-3, L3.6pl, and Panc-1) cancer
cell lines and NIH3T3 cells were from ATCC (Mana-
ssas, VA). Madin Darby canine kidney (MDCK) cells
stably expressing RON or RON160 (M-RON or M-
RON160 cells) were established as previously described
[15]. Human MSP was provi d e db yD r .E .J .L e o n a r d
(National Cancer Institute, Bethesda, MD). Mouse
monoclonal antibodies (mAb) specific to the RON
extracellular sequences (clones Zt/g4 and Zt/c1) were
used as preciously described [30]. Rabbit IgG antibody
specific to RON C-terminal peptide was described pre-
viously [31]. Recombinant human furin was from New
England BioLabs (Ipswich, MA). PD98059 (PD),
SB203580 (SB) and wortmannin (WT) were from Cal-
biochem (San Diego, CA). Mouse mAb specific to phos-
pho-tyrosine (PY-100), phospho-Erk1/2, AKT, and other
signaling proteins were from Cell Signaling (Danvers,
MA). Rabbit or goat IgG antibodies specific to E-cad-
herin, vimentin, or b-actin were from BD Transduction
Laboratories (Lexington, KY).
Reverse Transcription (RT)-Polymerase chain reaction
(PCR) and DNA sequencing
RT-PCR was performed as previously described [32].
Briefly, total RNA was isolated from individual cell lines
using Trizol (Invitrogen, CA). RT was carried out using
2 μg of total RNA with a SuperScript Preamplification
kit (Invitrogen). PCR was conducted by using a pair of
oligomers to amplify RON160 or RON
E5/6in cDNA frag-
ments [32]. Amplified cDNA fragments were subcloned
into the pGEM-T-easy vector (Promega) and sequenced
at the Texas Tech University DNA Sequence Core facil-
ity (Lubbock, TX).
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E5/6in cDNA and its
expression in MDCK cells
The complete RON
E5/6in cDNA was constructed by
replacing a fragment in the wild-type RON cDNA with
an amplified 0.6 Kb fragment to create the full-length
RON
E5/6in cDNA as previously described [32]. Transfec-
tion of MDCK cells with RON
E5/6in, selection of stable
cell lines, and Western blot analysis of protein expres-
sion were conducted as previously described [13].
Immunoprecipitation and Western blot analysis
These methods were performed as detailed previously
[31,32]. Cellular proteins (250 μg/sample) were used for
immunoprecipitation by Zt/g4 (2 μg/sample) coupled to
protein G Sepharose beads. Individual proteins were
detected using specific antibodies in Western blot analy-
sis under reduced conditions. Membranes were also
reprobed with rabbit IgG antibody to b-actin to ensure
equal sample loading [31,32].
Immunofluorescent cell surface analysis
Fluorescent cell surface analysis was carried out as pre-
viously described [33]. Briefly, M-RON, M-RON160 or
M-RON
E5/6in cells (1 × 10
6 cells/ml) were incubated
with Zt/g4 (1 μg/sample/ml) followed by goat anti-
mouse IgG coupled with FITC. Fluorescent intensity
was determined by FACscan (Becton Dickinson) analysis
as previously described [33]. In all assays, normal mouse
IgG was used as the negative control.
Protein micro-sequencing
M-RON and M-RON
E5/6in cells (3 × 10
6 cells/ml) in
DMEM were treated with 0.05% of trypsin for various
times. Cellular proteins (350 μg/sample) from lysates of
M-RON or M-RON
E5/6in cells were first immunopreci-
pitated by Zt/g4 (1 μg/sample) coupled with protein G
Sepharose beads [31]. Samples were then separated in
8% SDS-PAGE under reduced conditions followed by
transfer to a poly(vinylidene difluoride) membrane (Pro-
blott; Applied Biosystems) [34]. The protein bands were
identified, marked and analyzed directly on an Applied
Biosystems 473A protein sequencer fitted with a reac-
tion cartridge specifically designed for poly(vinylidene
difluoride) bound samples at the Colorado State Univer-
sity Core facility (Ford Collin, Co).
Cell migration assays
Wound healing assays were used to determine the abil-
ity of cells to migrate to cover the open space as pre-
viously described [24]. Cells were stimulated with MSP
(2 nM) for 16 h. The percentage of open spaces covered
by migrated cells was determined as previously
described [24].
Bioassays for cell focus formation and anchorage-
independent growth in soft agar
Both assays were performed as previously described [13].
For focus formation, cultured NIH-3T3 cells in 30 mm
diameter dish were transiently transfected with the
pcDNA3.1 expression vector containing RON, RON160,
or RON
E5/6in cDNA, respectively. Foci were counted
after cells were maintained in DMEM with 1% FBS for
18 days. For colony formation, cells (2000 cells/dish) in
2 ml DMEM with 5% FBS and 0.3% agarose were seeded
in a 30 mm diameter culture dish containing 0.7% agar-
ose. The colony numbers were determined 18 days after
initiation of cell culture.
Results
Different RON mRNA transcripts with alterations in the
first IPT unit are present in colon, breast, and pancreatic
cancer cells
Previous studies have shown that deletion of the first
IPT unit coded by exons 5 and 6 results in formation of
oncogenic variant RON160 [13]. To determine if other
types of alterations exists in the first IPT unit, total
RNA isolated from a panel of twelve cancer cell lines
was subjected to RT-PCR analysis. The cDNA fragments
were amplified by using primers that cover the first IPT
unit and its surrounding sequences (
+1646 to
+2184
from exons 4 to 7). Results in Table 1 and Figure 1A
are the summary of the RT-PCR analysis. Three cDNA
fragments, Fgm-I (0.54 kb), Fgm-II (0.21 kb), and Fgm-
III (0.6 kb) were obtained (data not shown). The cDNA
sequence analysis indicated that Fgm-I encodes a por-
tion of wild-type RON, which was amplified in all eleven
cell lines known to express RON. MCF-7 cells do not
express RON [32] and were used as a negative control.
Fgm-II showed a deletion of 109 amino acids coded by
exons 5 and 6 and was observed in HT-29, SW620,
SW837 and Du4475 cell lines. Expression of this tran-
script was consistent with previous studies showing the
existence of RON160 in colon and other cancer cell
lines [13].
An interesting finding was the detection of a 0.6 kb
Fgm III from HT-29, SW620, Du4475, and Panc-1 cells.
Sequence analysis showed an insertion of 20-amino
acids (60 nucleotides) between the last amino acid of
exon 5 (Arg
627) and the first amino acid of exon 6
(Pro
628) (Figure 1A and Table 1). The inserted
sequences were identical among fragments amplified
from four cell lines. By comparing the genomic
sequence of the RON gene [25], it was determined that
60 nucleotides belong to the intron sequence between
exons 5 and 6, which were retained during the splicing
process. The resulting product is a RON mRNA tran-
script, which should be expressed as a novel RON
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RON
E5/6in). Thus, three specific mRNA transcripts
encoding wild-type RON, RON160, and RON
E5/6in were
amplified from several cancer cell lines. Schematic
representations of RON160 and RON
E5/6in with deletion
or insertion in the first IPT unit are shown in Figure
1B. Clearly, RON
E5/6in i san o v e lv a r i a n tt h a th a sn o t
been previously reported.
Although wild-type RON and RON160 were detected
by Western blot analysis using rabbit IgG specific to the
RON C-terminus, we were unable to distinguish wild-
type RON and RON
E5/6in due to small differences in
their protein size (data not shown). Moreover, since the
molecular mass of RON
E5/6in is almost identical to that
o fw i l d - t y p eR O N ,w ew e r eu n a b l et oc o n f i r mi ft h e
RON
E5/6in protein is expressed in RT-PCR positive cell
lines. Nevertheless, existence of mRNA transcripts for
RON160 and RON
E5/6in provides us an opportunity to
study the significance of the first IPT alterations in reg-
ulating RON-mediated activities.
RON160 and RON
E5/6in are both expressed on cell surface
but showed different phosphorylation status
Since the deletion of the first IPT unit leads to onco-
genic conversion [13], we wanted to know if insertion in
the same domain has a similar effect. To this end, the
cDNA encoding the RON
E5/6in was constructed by
replacing a fragment in wild-type RON cDNA with the
cloned Fgm-III and then stably transfected into MDCK
cells. Results from Western blot analysis showed that
both RON160 and RON
E5/6in were processed from sin-
gle-chain precursor into mature a/b heterodimer (as
evident by the presence of the b-chain) (Figure 2A).
These indicate that deletion or insertion does not affect
the exposure of a/b chain cleavage site (Lys
304-Arg-Arg-
Arg) on the surface of RON for enzymatic conversion.
Interestingly, a protein with molecular mass of 110 kDa
was observed in M-RON
E5/6in cells, which is not
observed in RON or RON160 expressing cells (this var-
iant RONp110 will be described later in detail). This
suggests that the processing of RON
E5/6in differs from
RON160. Immunofluorescent analysis showed that both
RON160 and RON
E5/6in are expressed on the cell sur-
face (Figure 2B), suggesting that synthesized receptors
were transported from cytoplasm to cell surface. Analy-
sis of protein phosphorylation revealed that RON160 is
constitutively active with high levels of tyrosine phos-
phorylation. MSP stimulation only marginally enhanced
its phosphorylation status (Figure 2C). In contrast,
RON
E5/6in was not phosphorylated in unstimulated cells.
MSP stimulation was required for its phosphorylation
(Figure 2C). These results indicate that deletion in the
first IPT unit causes spontaneous activation. However,
the insertion does not transform the protein into a con-
stitutively active variant. At intracellular signaling,
RON
E5/6in-mediated activation of Erk1/2 and AKT relied
on MSP stimulation (Figure 2D). In contrast, Erk1/2 and
AKT were constitutively phosphorylated in M-RON160
cells. MSP only slightly enhanced RON160-mediated
phosphorylation of Erk1/2 and AKT. Taken together,
these results demonstrate that insertion and deletion in
the first IPT unit do not affect transportation, matura-
tion, and cell surface expression of RON160 and
RON
E5/6n. However, the deletion resulted in constitutive
activation of RON160. In contrast, the insertion failed to
convert RON
E5/6in into a constitutively active variant.
Table 1 Identification of RON mRNA transcripts with alterations in the first IPT Unit in colon, breast, and pancreatic
cancer cells.
Types of RON mRNA transcripts*
Cancer Cell lines Tissue sources Wild type (0.54 kb) Deletion of exons 5 & 6 (0.21 kb) Insertion btw exons 5 & 6 (0.6 kb)
HT-29 Colon ++ +
SW620 Colon ++ +
HCT116 Colon + --
SW837 Colon ++ -
T-47D Breast + --
Du4475 Breast ++ +
HCC1937 Breast + --
ZR-751 Breast + --
MDA-MB231 Breast + --
BxPC-3 Pancreatic + --
L3.6pl Pancreatic + --
Panc-1 Pancreatic + - +
MCF-7 Breast - - -
*The mRNA isolation and RT-PCR analysis were performed as detailed in Materials and Methods. Cell lines expressing mRNA transcripts of RON and its variants
are marked as +. Deletion and insertion were determined by comparison with published RON gene sequences [25].
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Page 4 of 15Figure 1 Identification and cloning of RON mRNA transcripts with alterations in the first IPT domain in cancer cell lines. A) Partial
sequences of amplified RON cDNA fragments. The sequences show a deletion of 327 nucleotides coded by exons 5 and 6 and an insertion of
60 nucleotides between exons 5 and 6. The deleted sequences that encode 109 amino acids by exons 5 and 6 are italicized (as detected in
RON160 cDNA). The inserted sequences encoding 20 new amino acids are underlined (as detected in RON
E5/6in cDNA). The beginning and
ending of the first IPT unit are indicated. The first nucleotides of exons 5, 6, and 7 are marked with an arrow. The amino acids that act as the
digestive site for trypsin-like serine proteases, which led to generation of RONp110, are shown in bold. B) Schematic representation of wild-type
RON, RON160, RON
E5/6in, and RONp110. Mature RON contains a sema domain (localized in both a and b-chains) followed by a PSI motif and
four IPT units. The deletion of exons 5 and 6 and the insertion between exons 5 and 6 in the first IPT unit are indicated with arrows. Cleavage
by trypsin-like serine protease in the digestive site results in a truncated variant known as RONp110. Two tyrosine residues (Y1353 and Y1360) in
the C-terminal tail are indicated. TM: transmembrane domain; TK: tyrosine kinase domain.
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E5/6in and RON but
not from RON160 in response to cell-derived proteases
A ss h o w ni nF i g u r e2 A ,t h ee x p r e s s i o np a t t e r no f
RON
E5/6in differs from wild-type RON and RON160
with an additional RON variant (RONp110). Analysis
by protein micro-sequencing revealed that RONp110
is a proteolytic cleaved and truncated protein missing
the majority of the extracellular sequence (Figure 1A
and 1B). The N-terminal first amino acid was Lys
632,
which is in the middle of the first IPT unit coded by
exon 6. Consistent with these analyses, we detected a
soluble RON isoform with molecular mass of ~80 kDa
(designated as RON
Er80) from culture fluids under
non-reduced conditions. This protein was not
observed in cells expressing RON
E5/6in (data not
shown). These results indicate that RON
E5/6in is pro-
teolytically processed to form RONp110 and RON
Er80.
Analysis of amino acids adjacent to Lys
632 showed
that the sequence Val-Pro-Arg-Lys
632-Asp-Phe-Val is
highly susceptible to digestion by trypsin-like serine
proteases [35]. This indicates t h a ti n s e r t i o ni nt h ef i r s t
IPT unit facilitates the exposure of this particular
sequence for potential digestion by trypsin-like serine
proteases. In contrast, deletion of the first IPT unit
eliminates this sequence. Therefore, RON160 is resis-
tant to trypsin-like serine proteases.
Figure 2 Expression, localization, and phosphorylation of RON160 and RON
E5/6in in MDCK cells. A) Expression of RON160 and RON
E5/6in in
MDCK cells. Cell lysates (50 μg/sample) from M-RON, M-RON160, or M-RON
E5/6in after 72 h incubation were analyzed by Western blot analysis
using rabbit IgG antibody to RON C-terminus [29]. b-actin was used as the loading control. Both pro- and mature proteins were observed. The
presence of RONp110 in M-RON
E5/6in cells was indicated. B) Immunofluorescent analysis of RON, RON160, and RON
E5/6in expression on cell
surface. Cells (1 × 10
6 cells per sample) were incubated with 1 μg/ml of Zt/g4 specific to the RON extracellular domain [30]. Goat-anti-mouse IgG
coupled with FITC was used as the secondary antibody. MDCK cells were used as the negative control. Fluorescent intensity of individual
samples was analyzed by FACScan. C) Spontaneous and MSP-induced phosphorylation of RON, RON160, and RON
E5/6in in MDCK cells. Cells (3 ×
10
6 cells/sample) after 72 h incubation were stimulated at 37°C with or without 2 nM of MSP for 10 min. Cellular proteins (250 μg/sample) were
immunoprecipitated with Zt/g4 (1 μg/ml) followed by Western blot analysis using anti-phosphotyrosine mAb PY-100. Membranes were also
reprobed with rabbit anti-RON C-terminus antibodies as the loading control. D) Effect of MSP on RON, RON160, and RON
E5/6in-mediated
phosphorylation of downstream signaling proteins. Cells were stimulated for 10 min with MSP as described in C. Western blot analysis using
antibodies to regular or phosphorylated Erk1/2 and AKT were carried out as previously described [29]. Data shown here are from one of three
experiments with similar results.
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and M-RON
E5/6in cells followed by Western blot analy-
sis. M-RON cells were used as the control. Results in
Figure 3A showed that RON expression in MDCK cells
did not result in RONp110 formation. RONp110 was
only produced when M-RON cells were treated with
trypsin in a time-dependent manner. In contrast,
RONp110 existed in M-RON
E5/6in cells in the absence
of trypsin. The amounts of RONp110 were dramatically
increased after trypsin treatment. As expected,
RONp110 was not produced from RON160 when M-
RON160 cells were treated with trypsin. Results in
Figure 3A further confirmed that treatment of cells with
soybean trypsin inhibitor (STI) blocks trypsin activity,
which inhibits RONp110 generation. Thus, RONp110
generation is mediated by enzymatic cleavage at the
digestive site of Val-Pro-Arg-Lys
632-Asp-Phe-Val.
Expression of RON
E5/6in spontaneously causes
RONp110 formation. Both RON and RON
E5/6in have
the potential to produce RONp110 after exogenous
trypsin treatment.
To determine the source of trypsin-like proteases, M-
RON160, and M-RON
E5/6in cells were incubated for 72
h in serum-free or FBS-containing medium. M-RON
cells were used as the control. Results from Western
blot analysis showed that culture of M-RON cells with
increased amounts of FBS does not result in any
RONp110 formation, indicating that RONp110 is not
produced by M-RON cells under regular culture condi-
tions containing FBS (Figure 3B). Similarly, RONp110
was not generated from M-RON160 cells in the pre-
sence or absence of serum. In contrast, RONp110 was
produced in M-RON
E5/6in cells cultured with serum-free
medium (Figure 3C). Addition of serum did not further
increase RONp110 production by M-RON
E5/6in cells.
These results suggest that FBS is not the source for
Figure 3 Generation of RONp110 from RON
E5/6in but not from RON160 in response to trypsin or cell-derived trypsin-like proteases. A)
M-RON, M-RON160 and M-RON
E5/6in cells (2 × 10
6 cells per sample) were incubated for 24 h and then treated with 0.05% of trypsin in the
presence or absence of STI in DMEM at 37°C for 5, 15, and 30 min. Proteins (50 μg per sample) from cell lysates were analyzed by Western blot
analysis using rabbit anti-RON antibody. B) Cells were incubated for 72 h and then treated at 37°C with different amounts of FBS in DMEM for
15 min. Western blot analysis was performed as described in B. C) Effect of STI on RONp110 formation mediated by cell-associated proteases. M-
RON
E5/6in cells in serum-free DMEM were treated at 37°C with different amounts of STI for 48 h. Levels of RONp110 in cell lysates were
determined by Western blot analysis as detailed in C. Results shown here were from one of three experiments with similar results.
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proteases are responsible for the generation of
RONp110 in M-RON
E5/6in cells.
To determine if cell-derived proteases are sensitive to
inhibition by trypsin inhibitors, M-RON
E5/6in cells in
serum-free medium were treated with different amounts
of STI. Results in Figure 3C showed that STI inhibits
RONp110 formation in a dose-dependent manner, sug-
gesting that although the nature of the enzyme is
unknown, cell-associated trypsin-like protease(s) is
responsible for the conversion of RON
E5/6in into
RONp110.
Cytoplasmic pro-RON160 and pro-RON
E5/6in are
differentially converted into a/b mature protein
Proteolytic conversion of pro-RON into two-chain
mature RON is required for expression on the cell sur-
face and for interaction with MSP [8,36]. By analyzing
the levels of precursor and b-chain, the conversion pro-
cess can be determined. Results in Figure 4A showed
the different patterns of proteolytic conversion of pro-
RON160 and pro-RON
E5/6in in MDCK cells. Using b-
chain as an indicator, conversion of pro-RON was seen
as early as 3 h, reached maximal level at about 12 h,
a n dt h e ns t a b i l i z e dt h e r e a f t e r. Proteolytic cleavage of
pro-RON160 was processed in a manner similar to pro-
R O N .T h em a t u r eR O N 1 6 0b-chain was observed after
initiation of cell labeling. Saturated levels of RON160 b-
chain were seen around 12 h and maintained thereafter.
In contrast, pro-RON
E5/6in conversion was significantly
delayed in comparison with pro-RON and pro-RON160.
Although trace amounts of converted products were
observed in the early stages of incubation, significant
amounts of RON
E5/6in b-chain were detected only after
cells were incubated for 24 h. Stabilized RON
E5/6in b-
chain was seen mainly at 72 h of incubation (data not
shown).
Proteolytic conversion of the MET precursor is
mediated by members of the subtilisin-like proprotein
convertase family such as furin, which has the preferred
Arg-X-Lys/Arg-Arg sequence as the cleavage site
[37,38]. We tested if delayed maturation is caused by
insensitivity of pro-RON
E/56in to furin-mediated clea-
vage. After purification by Zt/g4 immunoprecipitation,
individual samples of pro-RON, pro-RON160, and pro-
RON
E5/6in were treated with various amounts of recom-
binant furin at 37°C and the conversion was evaluated
by Western blot analysis. As shown in Figure 4B, pro-
RON and pro-RON160 were correctly cleaved by furin
in a dose-dependent manner. In contrast, pro-RON
E5/6in
was relatively insensitive to furin-mediated cleavage.
When treated with 0.6 unit/ml of furin, only small
amounts of pro-RON
E5/6in were converted to the mature
b-chain. Thus, pro-RON
E5/6in is relatively insensitive to
enzymatic cleavage by protein convertase furin.
Down-regulation of RON
E5/6in but not RON160 is
significantly accelerated upon anti-RON mAb engagement
The differences between RON160 and RON
E5/6in
prompted us to study if RON
E5/6in differs from RON160
in receptor internalization process. Anti-RON mAb Zt/
g4-induced RON internalization and degradation [39]
was used as the model. Results in Figure 5A show
a time-dependent internalization of RON160 and
Figure 4 Differential conversions of pro-RON160 and pro-RON
E5/6in expressed in MDCK cells. A) Time-dependent conversion of pro-
RON160 and pro-RON
E5/6in in MDCK cells. Individual cell lines (2 × 10
6 cells/sample) were treated with 0.05% trypsin for 30 min to eliminate
mature b-chain and then incubated with DMEM containing 10% FBS for variable hours. Cell proteins were subjected to Western blot analysis as
described above Figure 3. B) Proteolytic effect of furin on pro-RON160 and pro-RON
E5/6in. Purified pro-RON, RON160 and RONE
5/6in in DMEM
were incubated at 37°C with different amounts of furin for 5 h as previously described [37]. The samples were then subjected to Western blot
analysis as described above. Protein intensity was determined by VersaDoc Imagining software as previously described [28].
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E5/6in after Zt/g4 treatment. Quantitative values are
presented in Figure 5B. Zt/g4-induced RON internaliza-
tion was used as the control. After Zt/g4 treatment for
12 h, more than 80% of mature RON (evident by levels
of the RON b-chain) was internalized followed by degra-
dation. Zt/g4-induced RON160 internalization was sig-
nificantly delayed than that of wt-RON. Only 60% of
mature RON160 was down-regulated 12 h after Zt/g4
treatment. In contrast, the down-regulation of RON
E5/
6in was significantly accelerated. After Zt/g4 treatment
for 3 h, almost all mature RON
E5/6in was internalized
followed by degradation. These results suggest that
RON
E5/6in internalization and down-regulation is
significantly accelerated upon Zt/g4 engagement. In
contrast, RON160 displayed relative resistance to Zt/g4-
induced internalization and degradation.
Chemical inhibitors, concanamycin A (Ccm-A) and
lactacystin that specifically inhibit lysosome and pro-
teoasome-mediated protein degradation, respectively
[40,41], were used to determine how internalized pro-
teins were degraded. Results in Figure 5C show the pre-
ventive effect of Ccm-A on lysosome-mediated
degradation of RON, RON160, and RON
E5/6in in MDCK
cells. Although Ccm-A almost completely prevented Zt/
g4-induced down-regulation of RON and RON160, it
showed only a moderate effect on prevention of
Figure 5 Accelerated down-regulation of RON
E5/6in but not RON160 upon anti-RON mAb treatment: A) Zt/g4-induced receptor down
regulation. M-RON, M-RON160 and M-RON
E5/6in cells (2 × 10
6 cells per sample) were treated at 37°C with 10 μg/ml of Zt/g4 for various intervals.
Normal mouse IgG was used as the negative control. Cellular proteins (50 μg/ml per sample) from cell lysates were subjected to Western blot
analysis using rabbit anti-RON C-terminus antibody. B) Intensity of individual protein bands from different groups in A were compared and
plotted against various time points after Zt/g4 treatment. C) Preventive effect of Ccm A on Zt/g4-induced receptor down-regulation. Cells were
treated for 12 h as described above. Ccm A was added after initiation of Zt/g4 treatment followed by Western blot analysis. D) Preventive effect
of lactacystin on Zt/g4-inuced receptor down-regulation. Cells were treated for 12 h as described above. Lactacystin was added after initiation of
Zt/g4 treatment followed by Western blot analysis. Data shown here are from one of three experiments with similar results.
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E/5/6in degradation. Similar results were also
observed when proteoasome inhibitor lactacystin was
used (Figure 5D). In this case, lactacystin almost comple-
tely prevented RON and RON160 degradation. However,
degradation of RON
E5/6in was only partially prevented by
lactacystin. These results suggest that inhibition of lyso-
some or proteoasome-mediated degradation prevents Zt/
g4-induced RON and RON160 down-regulation. How-
ever, Ccm-A or lactacystin alone only partially prevents
Zt/g4-induced degradation of RON
E5/6in.
Functional differences between RON160 and RON
E5/6in in
regulating tumorigenic activities
Overexpression of RON and RON160 in epithelial cells
results in EMT-like phenotype [15,16], which is charac-
terized by reduced E-cadherin expression (epithelial
marker) and appearance of vimentin (mesenchymal pro-
tein) (Figure 6A). Such changes were also observed in
M-RON
E5/6in cells; in which vimentin is expressed and
levels of E-cadherin are reduced, although the levels of
expression were not as obvious as RON160. Morpholo-
gical analysis of cell shape also showed that RON
E5/6in
expression moderately causes cell morphological change
(Figure 6B). In contrast, RON160 expression signifi-
cantly altered cell morphologies. Scatter-like activities
mediated by RON160 upon MSP stimulation were more
significant in M-RON160 than in M-RON
E5/6in cells.
Results from analysis of cell migration showed that
expression of RON
E5/6in moderately increases sponta-
neous migration of MDCK cells (from 0% to 48%).
The migration was further enhanced by MSP stimula-
tion (from 53% to 78%). In contrast, RON160 expres-
sion significantly increases spontaneous migration
(from 0% to 86%) (Figure 6C). MSP stimulation also
slightly enhanced this activity (from 86% to 93%).
Experiments using MAP kinase (PD98059) or PI-3
kinase (wortmannin) inhibitors further showed that
spontaneous or MSP-induced migration is preventable
by addition of PD98058 in all cell lines tested. In con-
trast, the effect of wortmannin was minimal. These
results demonstrate that RON160 is a much stronger
molecule than RON
E5/6in in induction of EMT and
cell migration.
We further studied the effect of RON160 and
RON
E5/6in on induction of focus formation and ancho-
rage-independent growth in soft agar using NIH 3T3
cells as the model. Results in Figure 7A showed that
transient expression of RON
E5/6in does not cause focus
formation by NIH-3T3 cells. MSP stimulation also failed
to induce focus formation in RON
E5/6in expressing cells.
These results were in line with cells expressing wild-
type RON, which is known as a non-transforming agent
[42]. In contrast, RON160 expression resulted in numer-
ous large-sized foci in transfected NIH3T3 cells.
Although MSP stimulation only moderately increased
the number of foci, it dramatically enlarged the size of
these foci.
Consistent with focus formation studies, results from
the soft agar experiments showed that RON
E5/6in expres-
sion does not lead to colony formation in soft agar. Addi-
tion of MSP only marginally stimulated a few small-sized
colonies grown in soft agar. In contrast, RON160 expres-
sion resulted in numerous colony growths in soft agar.
This effect was further enhanced after MSP is added to
cell culture. Moreover, the size of individual colonies was
much bigger than those in unstimulated 3T3-RON160
cells. Thus, like wild-type RON, RON
E5/6in is not a trans-
forming agent. Its expression is not sufficient to cause
focus and colony formation. In contrast, RON160 is a
strong transforming agent, which can be verified in both
focus and colony formation assays.
Discussion
The findings in this study demonstrate that alterations
in the first IPT unit in the RON extracellular sequence
results in two novel variants with different biological
profiles. Structurally, the IPT units consist of 80 to 100
amino acids and are featured by immunoglobulin-like
fold [25,43]. The IPT units are also found in certain
transcription factors such as NF-B and c-Jun, where it
is involved in protein-protein and/or protein-DNA
interaction [44]. The significance of the IPT units in
MET and RON has recently been discovered and
emphasized. The deletion of the first IPT unit in the
RON extracellular sequences converts wild-type RON
into oncogenic agent RON160 [13], although the under-
lying mechanisms are unknown. In MET, the fourth IPT
unit in the b-chain extracellular sequence harbors a high
affinity binding site for ligand HGF/SF [45]. HGF/SF
binding to this IPT unit is essential for induction of
MET activation [45]. Clearly, these findings illustrate the
importance of the IPT units in MET/RON-mediated sig-
naling cascades and tumorigenic activities. The data
from our current studies demonstrate that deletion or
insertion in the RON first IPT unit exerts different con-
sequences. Although deletion of the first IPT unit leads
to oncogenic conversion, insertion of 20 amino acids in
the same unit is not sufficient to transform the RON
protein into an oncogenic agent. However, insertion has
important impact on biochemical properties of RON.
We show that proteolytic conversion of pro-RON
E5/6in
into the two-chain mature protein by convertase furin is
significantly delayed upon precursor synthesis.
RON
E5/6in is also highly susceptible to cell-associated
serine proteases, which act on a short sequence leading
to generation of another variant RONp110. Moreover,
RON
E5/6in is internalized in an accelerated manner upon
anti-RON mAb engagement. Thus, alterations in the
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activity with different biochemical properties. In addi-
tion, generation of RON160 and RON
E5/6in provides an
opportunity to understand the roles of IPT units in reg-
ulating RON activation and activity, which could aid to
develop therapeutic agents for inhibition of RON-
mediated tumorigenic signaling.
Overexpression of RON in cancerous tissues is often
accompanied with the generation of aberrant mRNA
transcripts and their corresponding variants [13,14].
This has been considered as a mechanism by which
RON displays its protein diversity and regulates epithe-
lial homeostasis and malignant transformation [7]. A
survey by PCR of primary colon, lung, breast, and brain
Figure 6 Regulatory effect of RON160 and RON
E5/6in on EMT-like activities in MDCK cells: A) Effect of RON, RON160, and RON
E5/6in on
epithelial/mesenchymal protein expression. Proteins (50 μg per sample) from cell lysates prepared after 72 h incubation were subjected to
Western blot analysis using antibodies specific to vimentin and E-cadherin, respectively. Actin was used as the loading control. B) Effect of RON,
RON160 and RON
E5/6in on cell morphological changes. MDCK, M-RON, M-RON160 and M-RON
E5/6in cells were cultured for 24 h and then
stimulated with 2 nM of MSP for 48 h. Cell morphological changes were observed under Olympus Inverted microscope and photographed. C)
Effect of RON, RON160 and RON
E5/6in on spontaneous or MSP-induced MDCK cell migration. Cell monolayer was wounded as previously
described [29] and stimulated with or without 2 nM of MSP for 16 h. Chemical inhibitors such as PD98059 (10 nM, specific to MAP kinase) and
wortmannin (50 μg/ml, specific to PI-3 kinase) were added simultaneously. The wounded area covered by migrated cells was measured and
shown as % of the covered space. Data shown here are from one of three experiments with similar results.
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scripts encoding for known and unknown variants such
as RON165, RON160, and RON155 were wildly pro-
duced with relatively high frequencies in colon, breast,
lung and other types of cancers [46]. These variants are
mainly generated by aberrant mRNA splicing processes
that delete exon 11 (RON165), exons 5 and 6
(RON160), and exons 5, 6 and 11 (RON155) [7,46]. It
needs to be emphasized that exon 11 encodes 49 amino
acids belonging to the fourth IPT unit in the RON b-
chain extracellular sequences [25], which is required for
pro-RON maturation and cell surface localization [28].
Results in current studies demonstrate that alterations
in the first IPT unit in the RON protein are not a rare
occurrence. Among 12 cancer cell lines analyzed,
abnormality in the first IPT unit was observed in 5 cell
lines originating from colon, breast and pancreatic
tumors. These results are consistent with those from
analysis of primary tumor samples [14,46]. As reported,
deletion of exons 5 and 6 were observed in more than
50% of primary colon and 90% of brain tumor samples
but not in any normal tissues [14,46]. Further analysis
Figure 7 Effect of RON, RON160, and RONE5/6in on focus formation and anchorage independent growth: A)F o c u sf o r m a t i o nb y
transformed NIH3T3 cells. NIH3T3 cells (1 × 10
5 cells per dish) were transiently transfected with 3 μg of individual pcDNA3 expression vector
containing RON, RON160 or RON
E5/6in cDNA as previously described [13]. After incubation for 48 h, cells in 2% FBS-DMEM were stimulated with
or without 2 nM of MSP for additional 8 days. Focus formation was observed, photographed, and counted from individual groups. B) Colony
formation in soft agar by transfected NIH3T3 cells. The soft agar assays were performed as previously described [13]. NIH3T3, 3T3-RON, 3T3-
RON160, and 3T3-RON
E5/6in cells (1000 cells per dish) were seeded in soft agar with or without 2 nM of MSP for 25 days. Cell growth at ≥30 cells
per cluster was marked as a positive colony and counted.
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samples would be very informative. Although the under-
lying mechanisms of variant generation are currently
unknown, it is known that aberrant splicing and intron
retention in receptor tyrosine kinases occur commonly
in cancer cells [47,48]. Considering the oncogenicity is
of RON160 in vivo, such alterations with high frequen-
cies should have pathogenic significance in relevance to
tumor progression and malignant phenotypes.
From the viewpoint of disrupting the first IPT unit, it
was a surprise that RON
E5/6in differs significantly from
RON160 in terms of their biochemical and biological
properties (Table 2). First, RON160 and RON
E5/6in both
are cleaved from precursor into respective mature forms
but the kinetics of their processing is different (Figure
4). Pro-RON160 is cleaved at a rate similar to that of
pro-RON. In contrast, RON
E5/6in is matured at relatively
late stages. This is probably due to relative insensitivity
of RON
E5/6in to convertase furin-mediated proteolytic
cleavage. Such insensitivity could be due to sequence
alterations in the insertion. Site-directed mutagenesis
may verify if this is the case. Another possibility is that
insertion-induced conformational change may affect the
access of furin to the cleavage site located at a/b chain
junction. Second, under regular culture conditions con-
taining FBS, RON
E5/6in is the major source for genera-
tion of RONp110, although wild-type RON can also be
truncated by exogenous trypsin to form RONp110. This
suggests that the insertion causes the digestion site
(Val
629-Pro-Arg-Lys-Asp-Phe) in the first IPT unit more
accessible to cell-associated trypsin-like serine proteases.
As a post-translational truncated product, RONp110
misses the majority of the extracellular domains includ-
ing sema, PSI, and a large portion of the first IPT. MSP
stimulation hardly induced its phosphorylation (Figure
1B and 2C), which suggests that MSP may not bind to
RONp110. As expected, enzymatic digestion of RON or
RON
E56in by cell-derived trypsin-like proteases also pro-
duce a soluble ~80 kDa RON extracellular isoform
(RON
Er80) comprising the entire 35 kDa a-chain and a
~45 kDa partial extracellular b-chain. The isoform is
similar to a previously reported RONΔ85 [24]. RONΔ85
is a soluble truncated RON variant produced by a
mRNA transcript from a breast cancer cell line with
insertion of 49 nucleotides between exons 5 and 6 [24].
RONΔ85 has the inhibitory effect on MSP-induced
RON signaling events [24]. Considering their structural
similarities, it is reasoned that the RON
Er80 may have
the ability to regulate MSP-induced RON-mediated
activities. Currently, the role of RONp110 is unknown.
Interestingly, a similar variant of MET lacking the ecto-
domain but retaining the transmembrane and intracellu-
lar domains has been discovered in several cancer
samples [49]. This protein resides on the cell surface
and displays transforming, invasive, and tumorigenic
activities [49]. Third, deletion of the first IPT unit
results in constitutive tyrosine phosphorylation [13]. In
contrast, insertion does not convert RON
E5/6in into con-
stitutive phosphorylation. RON
E5/6in remains inactive
and requires MSP stimulation for phosphorylation and
activation of downstream signaling molecules such as
Erk1/2 and AKT (Figure 2C). Previous studies have
shown that deletion of first IPT unit results in imbal-
ance of cysteine residues in the extracellular sequences,
a possible reason for spontaneous dimerization leading
to constitutive phosphorylation [13]. Interestingly, a
cysteine residue was seen in the inserted 20 amino acids
in the RON
E5/6in molecule, which also causes an
Table 2 Biochemical and Biological Differences between RON160 and RON
E5/6in
Features Similarity and Difference*:
RON RON160 RON
E5/6in
mRNA in tumor cell lines 11 out of 12 in CC, BC, PC lines 4 out of 12 in CC, BC lines 4 out of 12 in CC, BC, PC lines.
First IPT unit wild-type exon deletion intron retention
Protein location cell surface cell surface cell surface
Activation MSP required constitutively active MSP required
Response to MSP strong moderate strong
Trypsin digestion sensitive no effect sensitive
Generation of RONp110 upon trypsin treatment no effect spontaneous and trypsin treatment
Furin treatment sensitive sensitive less sensitive
Intracellular degradation sensitive less-sensitive highly sensitive
Induction of EMT moderate effect strong effect moderate effect
Cell migration moderate effect highly effect moderate effect
Transforming activity no effect strong effect no effect
Colony formation no effect strong effect no effect
*CC, colon cancer; BC, breast cancer; and PC, pancreatic cancer.
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extracellular sequence. However, such addition does not
seem to affect the extracellular conformation of
RON
E5/6in. Thus, additional mechanism(s) is probably
involved in constitutive activation of RON160. Fourth,
RON160 is relatively resistant to anti-RON mAb-
induced internalization and degradation. In contrast,
RON
E5/6in is highly susceptible to Zt/g4-mediated degra-
dation (Figure 5). At present, we do not know mechan-
ism(s) responsible for such an accelerated process.
However, this is important for RON160 to sustain its
intracellular oncogenic signaling. As reported previously,
oncogenic RON variants created by mutations in the
kinase domain are highly resistant to ligand-induced
internalization [50]. We have previously found that anti-
RON mAb-induced down-regulation attenuates RON-
mediated tumorigenic signaling and motile-invasive
activities in colon cancer cells [39]. Thus, insertion in
the first IPT unit, through an unknown mechanism,
accelerates antibody-induced RON
E5/6in internalization
and degradation. Finally, insertion and deletion in the
first IPT showed differential effects on cellular activities.
From functional analysis, RON
E5/6in mediated EMT-like
activities are similar to those mediated by wild-type
RON. However, as judged by levels of vimentin and E-
cadherin, changes in cell morphologies, and cell motility,
RON160 is much more potent than RON
E5/6in in med-
iating these tumorigenic activities. Analysis of cell trans-
forming and anchorage-independent activities further
demonstrate that insertion in the first IPT unit does not
convert wild-type RON into a transforming agent. It is
the deletion that renders RON160 as the transforming
variant. As evident by in vitro transforming assays, the
number of foci mediated by RON160 was significantly
higher than that in RON
E5/6in expressed NIH3T3 cells.
Anchorage-independent growth by colonies in soft agar
was also observed only in RON160 expressing NIH3T3
cells. Thus, alterations in thef i r s tI P Tu n i t ,e i t h e rb y
insertion or deletion, result in two RON variants with
distinct structural and cellular activities.
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